Axert Paragraph IV Certification Filed
This article was originally published in The Pink Sheet Daily
Executive Summary
The first ANDA with a Paragraph IV certification was filed for Johnson & Johnson's Ortho McNeil division's migraine medicine Axert (almotriptan malate) Dec. 8